SCHEMBL10242946

SCHEMBL10242946

CCCCCCNC(=O)c1cccc(-c2ccco2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 6/20 0.57
L3MBTL1 Q9Y468 4/20 0.57
KDM4E B2RXH2 3/20 0.57
POLB P06746 3/20 0.57
HPGD P15428 3/20 0.57
ALOX15 P16050 3/20 0.57
CTDSP1 Q9GZU7 2/20 0.57
MEN1 O00255 2/20 0.57
MAPT P10636 2/20 0.57
KMT2A Q03164 2/20 0.57
MCL1 Q07820 2/20 0.57
CASP1 P29466 1/20 0.57
BLM P54132 1/20 0.57
CASP7 P55210 1/20 0.57
HSD17B10 Q99714 1/20 0.57
NAAA Q02083 2/20 0.57
GAA P10253 2/20 0.53
GLA P06280 1/20 0.53
APOBEC3A P31941 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243027 0.99 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242939 0.95 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242978 0.90 KEAP1 (0.58) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10242941 0.84 KEAP1 (0.61) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL131829 0.81 SMN1; SMN2 (0.87) SMN1; SMN2ALDH1A1L3MBTL1POLBMAPT
SCHEMBL6535127 0.81 SMN1; SMN2 (0.87) SMN1; SMN2ALDH1A1L3MBTL1POLBMAPT
SCHEMBL14048803 0.81 KEAP1 (0.57) ALDH1A1MEN1MAPTKMT2AHTT
SCHEMBL10242974 0.81 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL10243085 0.80 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL12250927 0.79 KEAP1 (0.57) ALDH1A1L3MBTL1KDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885ALDH1A1 1939/4885L3MBTL1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.